Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biofrontera (BFRI) Equity Average: 2021-2025

Historic Equity Average for Biofrontera (BFRI) over the last 3 years, with Sep 2025 value amounting to -$3.6 million.

  • Biofrontera's Equity Average fell 144.09% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 144.09%. This contributed to the annual value of $4.6 million for FY2024, which is 67.82% down from last year.
  • As of Q3 2025, Biofrontera's Equity Average stood at -$3.6 million, which was down 73.92% from -$2.1 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's Equity Average peaked at $23.2 million during Q4 2022, and registered a low of -$3.6 million during Q3 2025.
  • Moreover, its 3-year median value for Equity Average was $2.7 million (2024), whereas its average is $4.0 million.
  • Data for Biofrontera's Equity Average shows a peak YoY increase of 891.81% (in 2025) and a maximum YoY decrease of 175.85% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Biofrontera's Equity Average stood at -$3.0 million in 2021, then spiked by 869.17% to $23.2 million in 2022, then tumbled by 87.45% to $2.9 million in 2023, then soared by 70.86% to $5.0 million in 2024, then plummeted by 144.09% to -$3.6 million in 2025.
  • Its Equity Average stands at -$3.6 million for Q3 2025, versus -$2.1 million for Q2 2025 and $2.5 million for Q1 2025.